Filing identity and period
Important: The supplied filing is Signal Genetics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2016, filed May 16, 2016. It is not identified as a filing by Viridian Therapeutics, Inc.; confirm the issuer before relying on this summary.
Signal Genetics was a U.S. commercial-stage molecular diagnostics company whose revenue came primarily from its MyPRS multiple-myeloma test.
Financial performance and liquidity
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Net revenue | $818,000 | $645,000; up 27% |
| Cost of revenue | $629,000 | $760,000 |
| Gross profit (margin) | $189,000 (23%) | $(115,000) (-18%) |
| Operating expenses | $3.553 million | $3.257 million |
| Operating loss | $(2.735) million | $(2.612) million |
| Net loss | $(2.758) million | $(2.634) million |
| Net loss per share | $(0.26) | $(0.45), with weighted-average shares rising from 5.79 million to 10.74 million |
| Cash used in operations | $(2.222) million | $(1.109) million |
At March 31, 2016, cash and cash equivalents were $8.560 million, working capital was $7.229 million, total assets were $10.796 million, and stockholders’ equity was $8.339 million. Current liabilities totaled $2.443 million. Debt included a $1.105 million unsecured related-party note bearing 8% interest and due on demand, plus $67,000 of capital-lease obligations.
Material changes and management commentary
- Clinical and direct-billed test revenue increased to $773,000 from $225,000; related test volume rose 93%. Management attributed growth to new hospital customers, expanded commercial activity, and higher estimated selling prices for non-contracted payors.
- Research-testing revenue, primarily associated with UAMS, fell 90% to $40,000 as UAMS had less funding; management expected further declines in this revenue stream.
- Q1 2016 revenue included $142,000 of net favorable estimate changes relating to prior-year non-contracted payor revenue; Q1 2015 included $30,000 of net unfavorable changes.
- R&D expense increased 207% to $307,000, primarily from sponsored research. Selling and marketing rose 18% to $510,000; general and administrative expense rose 7% to $2.107 million.
- Cash declined $2.272 million during the quarter. Q1 2015 cash flow benefited from $9.346 million in net stock-offering proceeds, making financing and cash comparisons notably different.
Outlook, risks, and unusual items
Management forecast continued losses and negative operating cash flows but believed available cash would support operations for at least 12 months from the report date. It said additional financing or strategic investment might be needed as the business expanded; availability and terms were uncertain, and failure to obtain funding could require spending reductions and adversely affect business objectives. No material capital-expenditure commitments were reported.
- Revenue estimates depend on payor collection experience and contractual status; contractual allowances were 60% of gross revenue in Q1 2016 versus 51% a year earlier. Net accounts receivable were $490,000, while gross receivables were $2.935 million before $2.445 million of contractual allowances.
- Customer concentration remained relevant: UAMS-sourced revenue was 26% of net revenue, down from 77%; two other major customers represented 25% and 12% in Q1 2016.
- Testing materials came from one supplier, creating potential disruption risk. Management also cited challenges in expanding payor coverage, physician adoption, reimbursement levels, and competition from alternative tests.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. The filing states that the interim financial statements are unaudited.
Key facts for investors to verify
- Confirm the filing’s issuer: the document names Signal Genetics, Inc., not Viridian Therapeutics, Inc.
- Review the basis and collectability of non-contracted-payor revenue estimates, including the $142,000 favorable prior-period adjustment and aging of receivables.
- Assess cash runway against the reported $2.222 million quarterly operating cash use, continuing losses, and possible financing needs.
- Check the terms and demand status of the $1.105 million related-party note and the related-party governance disclosures.
- Track clinical test growth, declining UAMS research revenue, reimbursement expansion, customer concentration, and single-supplier exposure.